What is HC Wainwright’s Estimate for VIR FY2026 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.89) for the year, up from their previous estimate of ($1.89). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.99) EPS.

Other equities analysts have also recently issued research reports about the company. Zacks Research upgraded Vir Biotechnology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Needham & Company LLC increased their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Wall Street Zen upgraded shares of Vir Biotechnology from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Morgan Stanley lifted their price target on shares of Vir Biotechnology from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.57.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $13.15 on Wednesday. Vir Biotechnology has a 1 year low of $5.32 and a 1 year high of $14.38. The business has a 50-day moving average of $11.13 and a two-hundred day moving average of $9.68. The company has a market capitalization of $2.25 billion, a P/E ratio of -10.44 and a beta of 1.70.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.18. The business had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.98 million. During the same quarter in the prior year, the firm posted ($1.17) earnings per share. The business’s revenue was down 178.3% on a year-over-year basis.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, EVP Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the sale, the executive vice president owned 110,193 shares of the company’s stock, valued at $1,223,142.30. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC lifted its stake in Vir Biotechnology by 2.3% in the 3rd quarter. Voya Investment Management LLC now owns 63,855 shares of the company’s stock valued at $714,000 after acquiring an additional 1,457 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in Vir Biotechnology by 3.5% during the third quarter. Public Sector Pension Investment Board now owns 431,729 shares of the company’s stock worth $4,650,000 after purchasing an additional 14,520 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Vir Biotechnology during the third quarter worth $3,800,000. ACT Capital Partners L.P. bought a new position in Vir Biotechnology in the third quarter valued at $559,000. Finally, Russell Investments Group Ltd. increased its stake in Vir Biotechnology by 65.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 136,146 shares of the company’s stock valued at $1,522,000 after buying an additional 53,987 shares during the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir said its combination of tobevibart and elebsiran met the primary and secondary endpoints in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis D. The result strengthens the case for the regimen as a potential treatment and helped drive the recent surge in the shares. Article: Vir hepatitis D drug succeeds in first pivotal study
• Positive Sentiment: Morgan Stanley raised its price target to $28 and reaffirmed an “overweight” rating; HC Wainwright also reiterated its “buy” rating with a $22 target. These upgrades reflect optimism following the trial result.
• Neutral Sentiment: The Phase 3 success is an important milestone, but the recent rally may leave the stock vulnerable to profit-taking as investors assess the treatment’s regulatory prospects, market opportunity and competition. A recent analysis also questioned whether the shares are already fairly valued after the news. Article: Vir Biotechnology: Fairly Valued After Phase 3 Success?

About Vir Biotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.